HUTCHMED (China) Limited (AIM:HCM)
220.00
+10.00 (4.76%)
Nov 6, 2026, 4:35 PM GMT
HUTCHMED (China) Employees
HUTCHMED (China) had 1,790 employees as of June 30, 2026. That makes HUTCHMED (China) the 10,958th largest employer in the world and 256th in the United Kingdom.
Employees
1,790
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
231.21K GBP
Profits / Employee
7.53K GBP
Market Cap
1.91B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 1,790 | - | - |
| Dec 31, 2025 | 1,796 | -15 | -0.83% |
| Dec 31, 2024 | 1,811 | -177 | -8.90% |
| Dec 31, 2023 | 1,988 | -37 | -1.83% |
| Dec 31, 2022 | 2,025 | 265 | 15.06% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Haleon | 24,535 |
| Hikma Pharmaceuticals | 9,500 |
| Allergy Therapeutics | 584 |
| ECO Animal Health Group | 213 |
| Shield Therapeutics | 61 |
| Chill Brands Group | 11 |
| Provexis | 2 |
HUTCHMED (China) News
- 2 days ago - HUTCHMED (China) Transcript: Fireside chat - Transcripts
- 2 days ago - HUTCHMED's Sovleplenib Gets FDA Orphan Drug Status For Autoimmune Hemolytic Anemia - Nasdaq
- 2 days ago - Hutchmed says sovleplenib granted FDA orphan drug designation - TheFly
- 2 days ago - HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia - GlobeNewsWire
- 5 days ago - HUTCHMED Advances ORPATHYS-TAGRISSO Through EU, Japan Reviews - Nasdaq
- 5 days ago - Hutchmed announces filings for Orpathys accepted for review in Japan, Europe - TheFly
- 5 days ago - HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan - GlobeNewsWire
- 9 days ago - HUTCHMED (China) Limited Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia - Nasdaq